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Stakeholder-engaged process for refining
the design of a clinical trial in home
hospice
Jennifer Tjia1* , Margaret Clayton2, Germán Chiriboga1, Brooke Staples1, Geraldine Puerto1, Lynley Rappaport1 and
Susan DeSanto-Madeya3

Abstract
Background: Clinical trials in home hospice settings are important to build the evidence base for practice, but
balancing the burden and benefit of clinical trial conduct for clinicians, patients, and family caregivers is
challenging. A stakeholder-engaged process can help inform and refine key aspects of home hospice clinical trials.
The aim of this study was to describe a stakeholder-engaged process to refine, design, and implement aspects of
an educational intervention trial in home hospice, including recommendations for refining intervention content and
delivery, recruitment and enrollment strategies, and content and frequency of outcome measurement.
Methods: A panel of interprofessional (1 hospice administrator, 3 nurses, 2 physicians, 2 pharmacists) and 2 former
family caregiver stakeholders was systematically selected and invited to participate based on expertise, representing
2 geographically distinct hospices who were participating in the clinical trial. Teleconferences followed a
predetermined procedural sequence: 1. pre-meeting materials distribution and review; 2. pre-meeting email
solicitation of concerns in response to materials; 3. teleconference with structured and guided discussion; and 4.
documentation and distribution of minutes for accuracy review and future meeting guidance. Discussion topics
were distinct for each panel meeting. Written reflections on the stakeholder engagement process were collected
from panel members to further refine our process.
Results: Five initial biweekly teleconferences resulted in recommendations for recruitment strategy, enrollment
process, measurement frequency, patient inclusion, and primary care physician notification of the patient’s trial
involvement. The panel continues to participate in quarterly teleconferences to review progress and unexpected
questions and concerns. Panelist reflections reveal personal and professional benefit from participation.
Conclusions: An interprofessional stakeholder process is feasible and invaluable for developing home hospice
intervention studies, contributing to better science, successful trial implementation, and relevant, valid outcomes.
Trial registration: Clinicaltrials.gov, NCT03972163, Registered June 3, 2019.
Keywords: Stakeholder, Home hospice, Clinical trial, Outcome measurement, Deprescribing
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Background
Stakeholder engagement has emerged as an important
component of meaningful clinical research [1–3]. Multistakeholder engagement, where diverse groups of stakeholders take part in the research project, is defined as
“an iterative process of actively soliciting the knowledge,
experience, judgment and values of individuals selected
to represent a broad range of direct interest in a particular issue, for the dual purposes of creating a shared understanding and making relevant, transparent and
effective decisions.” [4] While growing literature describes the stakeholder engagement process [1, 2, 5–7],
methods and guidance for its use in palliative care and
hospice research are limited [8–10], particularly in the
important area of home hospice.
Clinical trials in home hospice are critical to building
the evidence base for practice. However, balancing the
burden and benefit of clinical trial conduct for clinicians,
patients, and family caregivers is an ongoing challenge.
This challenge is even more complex when designing a
feasible study to be executed in home hospice that engages hospice patients and their family caregivers and
presents an ideal situation for meaningful stakeholder
engagement. Questions to be addressed include: the optimal design of a high-yield, low burden, clinical
workflow-friendly approach to family caregiver-patient
recruitment at hospice admission; selection and frequency of appropriate family caregivers and patient outcome measures; and heterogeneity of hospice team
interactions that affect research implementation across
different hospice sites.
To address these issues, a highly effective stakeholder
engagement process was designed and implemented for
an NIH-funded pilot randomized clinical trial, Standardized Patient Centered Medication Review (SPECTORx)
in Home Hospice. The goal of SPECTORx is to reduce
complexity and increase appropriateness of medication
use for patients and family caregivers during home hospice care. In this paper, SPECTORx will be used as an
exemplar to describe and share a stakeholder engagement method and approach in the refinement of clinical
trial in home hospice. The Participatory Action Research
(PAR) framework [11, 12], served as a foundation for the
stakeholder engagement process. PAR is a research paradigm that puts stakeholders at the heart of the investigation process as collaborators who work together with
investigators to resolve challenging issues. A key goal in
PAR is authentic, bi-directional, and insightful engagement of stakeholders to enhance and enrich programmatic outcomes, in this case, the conduct of clinical
trials to ensure study results are meaningful and clinically relevant to target populations. It is a collaborative,
cyclical, reflective design process that focuses on problem solving, improving work practices, and
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understanding the effect of the research endeavor on the
participating partners. The work of PAR typically includes cycles of planning, action, reflection, and evaluation/observation, with each cycle informing subsequent
efforts. The intent of this manuscript is to describe our
methodological approach to stakeholder engagement
and to present the reflections of stakeholders regarding
the value of this model. The implication is that our approach can be replicated and/or adapted by other investigators in the field of palliative care and hospice trial
research.

Methods
Initial stakeholder engagement in SPECTORx - eligibility,
recruitment and study setting

The goal was to assemble a key stakeholder panel, inclusive of interprofessional clinicians and family caregivers
who participate in the care of home hospice patients. A
multi-stakeholder panel consisting of 1 hospice administrator, 3 nurses, 2 physicians, 2 pharmacists, and 2
former family caregivers was systematically recruited
and assembled to guide refinement of the study protocol
and implementation by sharing their expertise and experience with hospice medication management. The
composition of the panel was designed to include clinical, administrative, and front-line care delivery and care
recipient perspectives. Deliberately recruiting a minority
of physicians, equal in number to pharmacists and family
caregivers, and fewer than nurses, was intended to mitigate the inherent power differential that can arise in interprofessional activities that include physicians [13].
The intention of having more than one family caregiver
was to increase the weight of the family’s voice in the
deliberation process relative to the clinicians’ voice. We
did not include hospice patients on the panel because of
their inherently vulnerable health status and limited life
expectancy, which was much shorter than the planned
time horizon of the stakeholder process. The final size of
the stakeholder panel (n = 10) was also designed to be
larger than the size of the investigator team (n = 6, 3 investigators plus 3 research staff) in order to avoid a
negative imbalance in the ratio of stakeholder panelists
relative to the investigator team during the meetings. To
address geographic variation in clinical practice, we
sought to include stakeholder panel members, in roughly
equal number, from both of the 2 geographically distinct
hospice agencies participating in the SPECTORx pilot
trial in the US.
Individuals were eligible for the stakeholder panel
using the following criteria: hospice administrators (i.e.
executive or clinical director) actively employed by the
hospice agency; nurses employed by the hospice (i.e. not
per-diem) and providing > 24 h/week of in-home clinical
care; physicians serving as the hospice medical director;
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pharmacists providing services primarily to the hospice;
and former family caregivers needed to be Englishspeaking, have provided > 50% of care for a family member who died > 3 months from the time of recruitment
and be without complicated grief by the Inventory of
Complicated Grief scale [14].

Structured meeting procedures

The interprofessional and family caregiver stakeholder
panel was convened every 2 weeks for 3 months prior to
the start of the pilot trial using a structured procedure
for teleconferences. The panel met with the entire investigative team during each meeting. Meetings were designed to follow a cyclic structure that fostered a sense
of familiarity within the panel and allowed each member
to better understand the panel process of soliciting input
from all stakeholders. For example, each meeting opened
with a welcome and greeting, followed by a very brief
summary of decisions to date, then an introduction of
the meeting topic followed by points for discussion related to the day’s topic. After panel discussions about
design and implementation procedures were completed
in the first 4 bi-weekly meetings, the research team proposed, and the stakeholder panel agreed, to continue
meeting quarterly to review unexpected questions and
concerns about the content of the SPECTORx intervention, informational materials, and trial protocol.
The initial team meeting established relationships and
negotiated rules for engagement. To facilitate relationship building, the initial meeting started with personal
introductions which included stories about why the panelists were involved with the project based on personal
experiences. Subsequent meetings started with personal
check-ins, and then followed a sequence of procedures
for appropriate and efficient review of key program
questions. This sequence is listed in Fig. 1. The video
teleconference meetings were digitally recorded for accuracy of minutes. To acknowledge the time commitment and opportunity cost that each meeting entailed,
all participants were sent a $50 electronic gift card following their participation in each 1–1.5-h stakeholder
engagement session. This amount was selected to be
equal across all participants and not be coercive, with
the intent of communicating value to each member.
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Meeting topics

The goal presented to the stakeholder panel was to
finalize a pre-screened trial protocol prior to conducting
the SPECTORx medication intervention trial [15]. Stakeholder recommendations were solicited in a sequential
fashion to: a. refine content and delivery of the SPEC
TORx intervention, b. ensure recruitment and enrollment strategy was acceptable and feasible, and c. determine content and frequency of outcome measurement.
Stakeholder panel members were presented with general
information about each topic and key questions to guide
the discussions described herein (Table 1).
SPECTORx content and delivery

While the key content of the intervention focused on 3
topics selected a priori, (Table 2) Panel discussions were
used to gain insight into educational content delivery,
including issues regarding provision of CE/CEU/CME,
targeting of frontline hospice clinicians, and how to best
deliver the education (e.g. in person vs online). Panel
questions included: What do you already do well? What
is challenging now? What would be helpful to
emphasize? The development of ancillary educational
materials, such as patient/family caregiver pamphlets
and clinician pocket reference cards, and how to implement an online community of practice for hospice clinicians was also discussed.
Recruitment and enrollment strategies

The optimal design of a recruitment strategy that is
high-yield, low burden, and clinical workflow-friendly
for family caregiver-patient dyads in home hospice admission is unclear. Recruitment and attrition are inherently challenging issues in palliative care research [16,
17] While family caregiver-patient dyads have been successfully enrolled in prior home hospice studies [18, 19],
this typically occurred at the 4th or later home visit [11].
Further, while a two-step recruitment process that starts
with a brief, standardized, ‘interest in research’ screen in
the ‘hospice admission packet’ to refer family caregiverpatient dyads for recruitment by trained research staff
[20], widespread acceptability is not established.
Some evidence suggests that universal screening on
admission is an effective procedure [20]. Our goal was to
refine the protocol so that it allowed for enrollment of

Fig. 1 Process for Stakeholder Meeting Material Review and Documentation

Tjia et al. BMC Medical Research Methodology

(2021) 21:92

Table 1 Key Content of SPECTORx Hospice Educational
Intervention
1. Family Caregivers Support for Medication Management
2. Determining Medication Appropriateness in Hospice

Page 4 of 9

Centered Care Communication Survey [24, 25]. Panel
questions included: Should we measure outcomes
among patients? If so, how often should we measure patient outcomes?

3. How to Have Deprescribing Conversations

Selection and frequency of patient outcome measures

family caregiver-patient dyads as close to hospice admission as possible, before many medication changes occur.
Panel questions included: When and where recruitment
should start; who should conduct recruitment; what level
of involvement from hospice clinicians is acceptable;
how to minimize burden on hospice staff; what past experiences for recruiting have worked well at your site;
what is the correct order for referral for recruitment;
and should enrollment be by telephone or an in-home
visit?

Selection and frequency of family caregiver outcome
measurement

Weighing the burden and benefit of administering different family caregiver outcomes assessments is critical as
family caregivers are already burdened with the grief of
their loved ones’ illness and their caregiving responsibilities. Options discussed with the panel included primary
data collection using well-validated family caregiver
measures [21], and the use of secondary data such as the
Consumer Assessment of Healthcare Providers and Systems (CAHPS®) [22], a hospice assessment that is routinely collected to measure consumer satisfaction. Key
candidate family caregiver measures for stakeholder
panel consideration were the family caregiver Medication Administration Hassle Scale [23] and the Patient-

Selection of appropriate patient outcome measures was
also challenging due to our intent to enroll a heterogeneous population whose hospice admitting diagnoses
have different trajectories [26] and varied abilities to
self-report. Unpredictability of disease trajectories [26,
27] affect measurement frequency decisions and levels of
missing data. Different abilities to self-report affect selection of disease-specific versus generic quality of life
(QOL) instrument choice [28]. A key question was
whether to only use medical record data for patient outcomes since these can be obtained with no burden to
the patient. Panel questions included: Should we measure outcomes among patients? If so, how often should
we measure patient outcomes?
Soliciting reflections of panelists regarding the
stakeholder engagement process

After the design process was completed and the trial was
underway, we asked the stakeholders to reflect on their
participation and consider authoring a manuscript describing their experience. While all of the stakeholders
were interested, some found this to be intimidating. To
ease their concerns and facilitate the paper-writing
process, the research team provided panelists with several written prompts about their involvement, including,
for example: How engaged were you in the process?
What are the benefits of this panel to nurses, staff,

Table 2 Participatory Action Research (PAR) Informed Approach to Stakeholder Panel Engagement, by Clinical Trial Stage
PAR Cycle
Phase

Stakeholder Panel Start-Up Trial Stage
Refining Protocol and Design

Trial Execution

Dissemination

Plan

• Recruit key members
• Plan timing and process/
procedures

• Define a priori protocol and design
questions for panel input

• Plan for updates and check-in

• Plan for interpretation of
analysis/results

Action

• Define rules for
engagement and
communication
• Personalize approach to
facilitate inclusion and
participation

• Present goals, questions/challenges • Present updates for
• Invite additions to agenda setting
recruitment, acceptability,
from panel
feasibility
• Execute recommendations from
prior cycles PAR cycles (if applicable)

• Present interim analysis/
results
• Engage in plan for
presentation and
dissemination

Reflection

• Discuss, reflect and make
recommendations for
refining process

• Discuss, reflect and make
recommendations for challenging
issues, addressing gaps

• Invite feedback on successes
and challenges

• Invite interpretation of
interim analysis and results

• Record process and minutes
from stakeholder meetings
• Measures of trial benchmarks
(e.g. retention, adherence to
intervention)

• Record process and
minutes from stakeholder
meetings
• Peer review of research
manuscripts and meeting
presentations

Evaluation/ • Record process and
• Record process and minutes from
Observation minutes from stakeholder
stakeholder meetings
meetings
• Review of protocol by investigators,
• Check in with panelists and IRB, study safety officers, and
investigator team
stakeholders
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patients, and caregivers? What challenges were there in
participating in the stakeholder panel or in the stakeholder process? Comprehensive synthesis of those reflections is beyond the scope of this paper, but a few
responses are included herein to provide empiric data
about the stakeholder experience, including successes
and challenges.

Results
Five stakeholder meetings were held prior to the start of
the pilot trial. The first meeting encompassed introductions and an overview of the clinical trial and study aims.
The second meeting focused on SPECTORx intervention
content and delivery, including measurement burden
and frequency. The third meeting focused on recruitment, informed consent, and data collection. The fourth
meeting focused on the proposed content and delivery
of family caregiver materials. The fifth meeting presented the refined content and protocol incorporating
stakeholder panel feedback. The meetings lasted 60–90
min and all but one meeting was attended by an average
of 9 stakeholder panel members.
Stakeholder engagement in the refinement of the clinical
trial protocol
Recruitment and enrollment strategy

Stakeholders were helpful in recruitment protocol refinement, providing a sounding board for variations in
procedures that needed to be developed to respectfully
accommodated differences between the study sites.
Flexibility and tailoring the recruitment and enrollment
procedures for participating hospice organizations and
even individual sites was important for the success of
this trial as each hospice had its own workflow and procedures for patient admission and enrollment. Further,
the two hospices differed in their philosophical approaches to medication management and deprescribing,
with one making changes very close to admission, while
the other waited to make changes over the ensuing
weeks. While all members of the stakeholder panel provided valuable insight into recruitment and enrollment
strategies, the clinician stakeholders, most notably the
nurses and physicians, had recommendations based on
their prior interactions and experiences with patients
and family caregivers in practice and research. Their recommendations were further validated by the family caregiver stakeholders. Decisions regarding telephone vs inperson recruitment and enrollment were also informed
by differences between the two hospice organizations.
Specifically, in-person recruitment was very challenging
in one hospice organization serving a rural community.
There was universal agreement for developing recruitment procedures that did not rely on front-line nursing
staff to minimize nurse burden.
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When presented with the option of universal screening
on admission [20], the idea was initially rejected by our
stakeholder panel as they felt patients and families
needed time to adjust to home hospice care and that approaching them with an invitation to participate in a research study up front could initially be overwhelming.
However, at the time of trial initiation, one hospice had
adopted a version of universal opt-out for patients and
families using an informational letter and opt-out form
in all admission packets. This allowed a research assistant to conduct recruiting calls among patients and families who did not opt-out. In summary, our stakeholder
panel agreed that local flexibility was the key recommendation to support successful recruitment and
enrollment.
Selection and frequency of outcome measurement

Family caregiver All members of the stakeholder panel
felt that assessing family caregiver medication difficulties
was a key outcome measure for the study. They recommended a frequency of every 2 weeks in the first month,
and then every 4 weeks. In addition, panel members recommended assessing satisfaction with hospice care following study completion (i.e. post-death of the family
member).
Patient Stakeholder panel members suggested evaluating medication use and changes for patients, as well as
health service utilization (e.g. emergency department
visits and hospitalizations). All members of the stakeholder panel clearly stated that direct patient engagement for data collection was critical in this trial because
the patient is the most important element of the entire
project. They felt strongly that quality of life and symptom burden also be collected if the patient was willing,
and weighed in on the frequency of measurement (i.e.
every 2 weeks in the first month, and then every 4 weeks
until study completion or patient death). Input from
former family caregivers was especially helpful during
these panel discussions.
Stakeholder input for the educational intervention

Content A detailed description of the content of the
nurse driven SPECTORx educational intervention and
patient-family caregiver materials is beyond the scope of
this paper. Stakeholder input provided insight into augmenting key educational content in the following ways:
1. it was very important to reinforce communication
about deprescribing and to use established “off the shelf”
communication training materials, such as those from
End-of-Life Nursing Education Consortium (ELNEC);
and 2. staff training must address developing patient/
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family caregiver trust, including challenges in home hospice admission and how to build it. Stakeholder panel
members also felt it was important to cover communication regarding messaging of the trial so that staff felt
comfortable with recruitment and participation. Finally,
panel members suggested that pharmacists would benefit from additional information including rationale for
the deprescribing recommendations and tapering/discontinuation protocols.
Another unanticipated recommendation from the
stakeholders was the creation of patient/family caregiver
facing materials with medication-related information.
This was led by a subcommittee from the stakeholder
panel and resulted in a key additional intervention product for the clinical trial. This subcommittee was facilitated by a co-investigator and included a nurse,
pharmacist and family caregiver, to address concerns
from both the clinical and patient/family perspective.
Delivery For feasibility of delivery in the busy lives of
front-line clinicians, nurse stakeholders, with agreement
from the other clinician stakeholders, recommended that
the duration of hospice staff training for the SPECTORx
intervention should be short, with educational delivery
for no longer than 20-min per session. For example, a 1h training module was divided into 3 sessions of 20-min
duration. It was also recommended to have asynchronous online delivery to maximize use and ease of
completion.
Reinforcing content and retention

Stakeholders suggested that content could be accessed
and reinforced through electronic access via smartphones for content, in addition to summaries of the educational material on paper.
Stakeholder panelists’ reflections on the stakeholder
process

In individually solicited written responses from the panelists, members shared that they felt engaged in the
stakeholder-engaged research design and process in a
few ways: personally, through collaboration and teamwork, and in identifying the purpose and tasks to come
out of the meetings. This sentiment was common: “I feel
I was very engaged in the process.” Reported benefits to
nurses, staff, and caregivers included being involved in
producing a usable tool for deprescribing education for
hospice staff and family caregivers, being able to share
and receive a diversity of viewpoints, and ultimately
helping patients and family caregivers in reducing medication burden. The most notable challenges with the
process were finding and coordinating time to participate in stakeholder meetings, and juggling competing
with external clinical demands. Interestingly, at least one
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stakeholder felt there were no challenges with the
process. An unexpected outcome of the process was that
many stakeholders shared that they gained some personal and professional skills as a result of our meetings.
In unsolicited feedback, individual stakeholders
expressed appreciation for being asked to be part of the
stakeholder panel and having their input respected, valued, and incorporated into the clinical trial protocol,
and for family caregivers, being able to process and use
their experience to help others receiving home hospice.

Discussion
In this paper, we illustrate a PAR-grounded approach to
stakeholder engagement using a federally-funded pilot
clinical trial, SPECTORx, as an exemplar. The success of
our process, exemplified by the generation of practical
recommendations that strengthened the study’s trial
protocol, outcome measurement, and intervention content, as well as the relationship-building that fostered
enthusiastic buy-in for executing the trial and spawned
new collaborative projects, prompted reflection on the
process to identify key elements to consider using in
other palliative care and hospice trials going forward.
We summarize these stakeholder engagement elements
in the context of the typical PAR cycle with stages of
Planning, Action, Reflection and Evaluation. (Table 2)
While the cycle stages are presented linearly, it is important to note that the elements are cyclical and can
evolve organically to reflect the developing processes of
the collaborative work. For example, iterative rounds of
action and reflection may occur before a stage of
evaluation.
In the stakeholder planning and start-up phase, we
note that intentional recruitment of key players is essential to success. These include stakeholders who have
interest and unique knowledge of a topic and have
power to make a difference. For meaningful engagement,
we invited the stakeholders into the process of defining
the structure and rules for communication, as well as
take a personalized approach to ensure their inclusion
and participation. We invited stakeholders and investigators to reflect on tentative meeting procedures before
execution, and then recorded the recommendations for
agreement and final review. This helped to foster a sense
of shared commitment to the values and objectives of
the stakeholder engagement process. We accomplished
these tasks prior to and during our first stakeholder
meeting, before any discussion of research content
issues.
Throughout our process, the research team was sensitive to the historical imbalances of academic-participant
collaborations [29], hierarchical imbalances arising from
combining healthcare professionals and lay persons to
the same team, and interprofessional power imbalances
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deeply ingrained in healthcare systems [13]. Within the UK
context our design process might be labelled as ‘co-production’ of research [30, 31], with egalitarian participation and
voice being the goal throughout the research design process
from beginning (i.e. the research question) to end, we describe our process as collaborative [30], with the role of the
stakeholders being two-fold: adding valuable knowledge
and skills to the research process, and providing experiential information about the hospice environment in which
the study would be implemented and research findings will
be used [32]. As such, while our communication process
was meant to be as egalitarian as possible, the stakeholders
served in a consulting role providing contextual expertise,
and the research team drove the research process, without
“threatening the legitimacy of the scientific endeavor” [30].
.For example, in the pre-trial stage of refining the
protocol and design of the trial, we defined the a priori
questions for the panel in the planning stage, and then
presented them and invited additional agenda items
from the panel. The built-in flexibility to possible gaps
in the investigator team’s scope of perceived trial challenges highlights a key benefit of inviting others to the
clinical trial planning process. We engaged in a number
of cycles of ‘action, reflection and evaluation’ so that
each of the main areas of review received adequate focused discussion and actionable recommendations.
We are continuing with stakeholder engagement into
the trial execution phase, by presenting the final protocol and intervention content, and having periodic meetings to present updates about key trial benchmarks such
as recruitment and acceptability of the intervention.
With a goal of transparency, we presented both success
and challenges with the intent to reflect back the outcome of the prior PAR process and to solicit input on
refinements to the path forward.
We plan to, and recommend that others, continue the
stakeholder engagement process through the dissemination
stage. We include interpretation of analysis and interim results in this stage and recommend inclusion of the stakeholder panel in the planning of the scientific and nonscientific presentations both internal to the participating
study sites and external to scientific consumer. In each stage,
we continue to use a structured and efficient system for documenting and collating the input from the stakeholders to
reinforce transparency, authenticity, and integrity to the
process.
Most of the elements offered above are not inherently
novel, and are presented and organized differently in other
models of stakeholder engagement [1, 2, 5, 6]. However, we
would argue that this cyclical 4-stage model to be practical,
intuitive, and adaptable to the various types of studies including clinical trials [12]. We found that our process resulted in clinical practice-grounded protocol refinement
and an enhanced educational intervention for our trial.
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An examination of 50 PCORI trials requiring stakeholder engagement noted challenges to an engaged stakeholder process [6]. Most notable was the lack of time for
meetings. Language difficulties when levels of expertise
and experience varied were also noted. Using this knowledge, the research team spent considerable time in building a structured, yet flexible, method for stakeholder
engagement; thus challenges reported in other studies
were not as present in our process. This can be attributed
to our intentional efforts from the onset to foster a sense
of participation and community in panel discussions despite our geographic distance. These efforts included demonstrating respect for all opinions, soliciting opinions of
those who were more reticent, scheduling regular meetings in advance, using a predictable meeting structure,
emailing an agenda and discussion materials prior to the
meeting to allow participant preparation, and distribution
of minutes following the meetings to ensure all viewpoints
were accurately captured.
We note several limitations to our stakeholder engagement process. First is that our process was limited to 2
home hospice agencies in the US. Mitigating this limitation is that they were geographically diverse and represented both urban and rural populations. Second is that
we did not include patient participants in this panel because we were concerned that the burden of engagement
and the time horizon for the project did not fit well with
extremely limited life expectancies. In lieu of this, we recruited former family hospice caregivers who could reflect and represent the patient point of view. Third is
that the trial focused on medication management. However, we believe this process can work for other types of
trials as there is nothing inherent about medications that
should influence the stakeholder engagement process.
In conclusion, we demonstrate that meaningful, interprofessional stakeholder engaged process is feasible and
invaluable for home hospice intervention studies. Our
deliberate approach to selection of well-represented
stakeholder panel of interprofessional team members
and family caregivers, and predetermined procedural
meeting structure, is a method for optimally engaging
key hospice stakeholders to refine and successfully implement a clinical trial in home hospice with an overarching goal of ultimately improving palliative and end
of life research approaches. We believe the implication
for palliative care research is that it can contribute to
better science, justification for measures, and ultimately
better clinical outcomes. The process can also make for
more effective intervention content and relevance to
clinical partners, patients and family caregivers. Together
scientists and stakeholders can work together to develop
relevant and appropriate research to build an evidence
base for practice that will optimize end of life care for
patients and their caregivers.
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